The company’s pipeline includes investigational, preclinical and clinical stage anti-resistance agents based on novel mechanisms of action that include efflux pump inhibition and modulation of ...
Bart J et al. (2004) The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood–testis barrier and in primary testicular tumours. Eur J Cancer 40: 2064–2070 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback